DCAT Week ’18: CDMOs, CMOs, and Suppliers: Expansion Roundups

What have been the key developments from contract development and manufacturing organizations (CDMOs), contract manufacturing organizations (CMOs), and other suppliers and companies supporting pharmaceutical /biopharmaceutical development and manufacturing thus far in 2018?

This special issue of DCAT Value Chain Insights highlights key developments from January 2018 to April 3, 2018 of DCAT member companies making the news. 

Chemical/Chemical API Manufacturing

Biologics Manufacturing

Formulation/Drug Product Manufacturing

Packaging

General

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

New Drug Approvals in 2024: How Did The Industry Fare?

By
How did the industry fare with new drug approvals in 2023? What new drugs were approved by FDA and were approvals in pace with prior years? What was the mix between small molecules and biologics, and which companies and products made the mark? DCAT Value Chain Insights sums it up.

Have Your Company be A Newsmaker at DCAT Week

By
Applications are closing Wednesday February 5 for the DCAT Member Company Announcement Forum, a much-anticipated event at DCAT Week in which senior executives from DCAT Member Companies highlight major news announcements covering expansions, M&A, and other key strategic developments.

Industry Roundtable: Small-Molecule APIs

By
What are the key issues shaping the market for small-molecule drugs and related trends in manufacturing? An industry roundtable of senior executives share their perspectives on what is driving the market.

What Trending: Biologic-Based Drugs

By
What were the biologic-based drugs approved by FDA’s Center for Drug Evaluation and Research in 2024? Which companies and products crossed the regulatory finish line and how do they fit in the market?